The FDA approves Weltruza, Teva’s extended-release injectable suspension of olanzapine, for adults with schizophrenia. The new formulation is designed for once-monthly use via subcutaneous injection, offering a different administration route from the long-established oral form of olanzapine.
Teva states that Weltruza is the first and only once-monthly subcutaneous long-acting injectable olanzapine option. The company also highlights operational features including no loading doses, no oral supplementation, and no required post-injection monitoring, according to the available reports. The approval is based on results from Teva’s pivotal Phase 3 SOLARIS trial, which is described by outlets as supporting the therapy’s overall symptom outcomes.
While the coverage focuses on the approval and the product’s dosing and administration characteristics, the underlying common thread is the same: a decades-old antipsychotic gains a newer long-acting injectable formulation intended to simplify treatment for eligible adults with schizophrenia.
